Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report)‘s stock had its “market outperform” rating reiterated by equities researchers at JMP Securities in a research note issued on Friday, Benzinga reports. They presently have a $22.00 target price on the biotechnology company’s stock. JMP Securities’ price target would indicate a potential upside of 118.91% from the stock’s […]

Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They currently have a $6.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 265.85% from the stock’s previous close. Separately, […]

Royal Bank of Canada reiterated their outperform rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $77.00 price target on the biopharmaceutical company’s stock. Several other research analysts also recently weighed in on RARE. Stifel Nicolaus upped their price […]